Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis.
Gotorbe C, Segui F, Echavidre W, Durivault J, Blanchard T, Vial V, Pagnuzzi-Boncompagni M, Villeneuve R, Amblard R, Garnier N, Ortholan C, Serrano B, Picco V, Pouysségur J, Vucetic M, Montemagno C. Gotorbe C, et al. Among authors: montemagno c. Curr Oncol. 2024 Nov 20;31(11):7390-7402. doi: 10.3390/curroncol31110545. Curr Oncol. 2024. PMID: 39590175 Free PMC article.
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, Bourgoin M, Palenzuela H, Rossi AL, Ambrosetti D, Durivault J, Luciano F, Borchiellini D, Le Du J, Gonçalves LCP, Auberger P, Benhida R, Kinget L, Beuselinck B, Ronco C, Pagès G, Dufies M. Montemagno C, et al. J Exp Clin Cancer Res. 2024 Mar 19;43(1):86. doi: 10.1186/s13046-024-02984-2. J Exp Clin Cancer Res. 2024. PMID: 38504270 Free PMC article.
Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance.
Echavidre W, Durivault J, Gotorbe C, Blanchard T, Pagnuzzi M, Vial V, Raes F, Broisat A, Villeneuve R, Amblard R, Garnier N, Ortholan C, Faraggi M, Serrano B, Picco V, Montemagno C. Echavidre W, et al. Among authors: montemagno c. Cancer Res Commun. 2023 Dec 7;3(12):2483-2496. doi: 10.1158/2767-9764.CRC-23-0298. Cancer Res Commun. 2023. PMID: 38009896 Free PMC article.
Quantitative analysis of 99mTc-pertechnetate thyroid uptake with a large-field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions.
Serrano B, Amblard R, Beaumont T, Hugonnet F, Dietz M, Berthier F, Garnier N, Villeneuve R, Nataf V, Mocquot F, Montemagno C, Faraggi M, Paulmier B. Serrano B, et al. Among authors: montemagno c. EJNMMI Phys. 2023 Jul 31;10(1):45. doi: 10.1186/s40658-023-00566-3. EJNMMI Phys. 2023. PMID: 37522931 Free PMC article.
Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody.
Nachit M, Montemagno C, Clerc R, Ahmadi M, Briand F, Bacot S, Devoogdt N, Serdjebi C, Ghezzi C, Sulpice T, Broisat A, Leclercq IA, Perret P. Nachit M, et al. Among authors: montemagno c. Nat Commun. 2023 Feb 24;14(1):1062. doi: 10.1038/s41467-023-36776-7. Nat Commun. 2023. PMID: 36828835 Free PMC article.
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M. Hagege A, et al. Among authors: montemagno c. Cell Rep Med. 2022 Sep 20;3(9):100659. doi: 10.1016/j.xcrm.2022.100659. Cell Rep Med. 2022. PMID: 36130479 Free PMC article.
101 results